The recommendations indicate the necessity of using modern ultrafast acting insulin analogs, new diabetes technologies, namely insulin pumps with low glucose suspension function, and continuous glucose monitoring systems to improve metabolic control and reduce glucose variability. The gene discussed is INS; the disease is diabetes mellitus.